Algatech Licenses Rights to Beta Glucan Production Technology
09/08/2019
Algatech intends to launch several products using the algae-derived beta glucan, which will expand Algatech’s existing product offering and support its mission to develop commercial, microalgae-based products.
The growing demand for the fucoxanthin found in Algatech’s FucoVital has led to a tripling of Algatech’s fucoxanthin production capability. This is a significant step forward in meeting the growing demand for this powerful natural ingredient.
Algatech has licensed the rights and intellectual property related to the production of β-1,3-glucan from US biotech F3 Platform Biologics.
Algatech Ltd. has licensed the rights and intellectual property of technology belonging to F3 Platform Biologics that is designed to extract β-1,3-glucans from Euglena gracilis microalgae.
Fermentation expert Dr. Brad Cox, who has been instrumental in developing F3’s cutting-edge capabilities, will lead the Euglena project at Algatech and support its fermentation activity.
Microalgae-derived ingredient specialists Algatech are to license the rights to the production of β-1,3-glucan from microalgae Euglena gracilis from US biotech firm F3 Platform Biologics.